{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3348, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de074-73d3-7580-a7ce-0a58652f06ae", "docSlug": "132de07386a67d6d6fe037cdb62d07c7", "documentTitle": "AppHarvest | Results Presentation Deck | 13 slides", "authorId": "appharvest", "authorName": "AppHarvest", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-73d3-7580-a7ce-0a58652f06ae/9", "deckHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae", "deckAnchorHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae#slide-9", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-73d3-7580-a7ce-0a58652f06ae", "docSlug": "132de07386a67d6d6fe037cdb62d07c7", "documentTitle": "AppHarvest | Results Presentation Deck | 13 slides", "authorId": "appharvest", "authorName": "AppHarvest", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes non-GAAP financial measure disclaimer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-73d3-7580-a7ce-0a58652f06ae/10", "deckHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae", "deckAnchorHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae#slide-10", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-73d3-7580-a7ce-0a58652f06ae", "docSlug": "132de07386a67d6d6fe037cdb62d07c7", "documentTitle": "AppHarvest | Results Presentation Deck | 13 slides", "authorId": "appharvest", "authorName": "AppHarvest", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "timeline", "function": "plan_implementation", "notes": "Uses a timeline framework with illustrative icons for each year.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-73d3-7580-a7ce-0a58652f06ae/11", "deckHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae", "deckAnchorHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae#slide-11", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-73d3-7580-a7ce-0a58652f06ae", "docSlug": "132de07386a67d6d6fe037cdb62d07c7", "documentTitle": "AppHarvest | Results Presentation Deck | 13 slides", "authorId": "appharvest", "authorName": "AppHarvest", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide provides a standard non-GAAP financial reconciliation for AppHarvest.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-73d3-7580-a7ce-0a58652f06ae/12", "deckHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae", "deckAnchorHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae#slide-12", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-73d3-7580-a7ce-0a58652f06ae", "docSlug": "132de07386a67d6d6fe037cdb62d07c7", "documentTitle": "AppHarvest | Results Presentation Deck | 13 slides", "authorId": "appharvest", "authorName": "AppHarvest", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "filler", "function": "filler", "notes": "This is a branding/filler slide used in an earnings presentation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-73d3-7580-a7ce-0a58652f06ae/13", "deckHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae", "deckAnchorHref": "/decks/019de074-73d3-7580-a7ce-0a58652f06ae#slide-13", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/lf-Jx0aAFQ3VvknbyExwb4cendDE8laAH1DjOtX0DnM/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMmE4ODBhZDBjNTI2NTI3ZmU4YWE0OWM0MDI3MDIyNC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/1", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/tb-lp8F0I5fBBmixX6IsLi3K3QuM2ldOcSHbZTrkgic/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMmE4ODBhZDBjNTI2NTI3ZmU4YWE0OWM0MDI3MDIyNC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/OWcN49p8o7RE5-QVLjH33h9NJ-Td8RZjh0qpUi__tW8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMmE4ODBhZDBjNTI2NTI3ZmU4YWE0OWM0MDI3MDIyNC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/d326NUbCDiEgqhpKe1tEKmNuXElqY2nS36TuHCozzoc/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMmE4ODBhZDBjNTI2NTI3ZmU4YWE0OWM0MDI3MDIyNC9wMDAxLnBuZw" }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/2", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "key_messages", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/3", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "executive_summary", "function": "summarize", "notes": "Includes a legend for technical acronyms at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/4", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "roadmap", "function": "plan_implementation", "notes": "The chart uses a Gantt-style visualization to represent drug development stages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/5", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "context", "function": "establish_context", "notes": "The slide uses a four-column layout to structure the disease overview.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/6", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 6, "beatId": "9efdc5e5-038d-4e00-a590-e4a91a4f4a25", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies HBV as a significant unmet medical need (p6-7).", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "problem_statement", "function": "frame_problem", "notes": "Uses a geographic map and a nested circle diagram to illustrate the treatment gap.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/7", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-7", "loopMatches": [ { "to": 8, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b3e8d7b9-0084-4114-a08f-62c827296b2f", "evidence": "The document highlights the unmet medical need and the limitations of current treatments (p7-8).", "position": 0, "objective": "What is the cost of not addressing HBV?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 7, "from": 6, "beatId": "9efdc5e5-038d-4e00-a590-e4a91a4f4a25", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies HBV as a significant unmet medical need (p6-7).", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 7, "from": 7, "beatId": "bc9bddc7-5053-4090-b64a-3a6d7a5459d0", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Complication", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights the limitations of current treatments (p7).", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-oriented diagram to show how three distinct mechanisms of action (MOAs) combine to lead to a clinical outcome.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/8", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-8", "loopMatches": [ { "to": 8, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b3e8d7b9-0084-4114-a08f-62c827296b2f", "evidence": "The document highlights the unmet medical need and the limitations of current treatments (p7-8).", "position": 0, "objective": "What is the cost of not addressing HBV?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "Includes a schematic of the GalNAc-linker-RNAi construct and a bar chart illustrating the suppression of various HBV transcripts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/9", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide outlines the study structure for a clinical trial, categorizing cohorts by dosage and patient status (HBV DNA +/-).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/10", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 14, "from": 10, "beatId": "5dda647e-e3c1-4360-9757-fc347cc61491", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents data and results from clinical trials, including AB-729-001 (p10-14).", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data presented at EASL 2022 and AASLD 2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/11", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 14, "from": 10, "beatId": "5dda647e-e3c1-4360-9757-fc347cc61491", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents data and results from clinical trials, including AB-729-001 (p10-14).", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "traction", "function": "show_traction", "notes": "The slide displays longitudinal data for cohorts E, F, I, J, G, and K, highlighting individual patient responses and key clinical outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/12", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 14, "from": 10, "beatId": "5dda647e-e3c1-4360-9757-fc347cc61491", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents data and results from clinical trials, including AB-729-001 (p10-14).", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "traction", "function": "show_traction", "notes": "The slide displays 8 individual patient case studies (Pt 46, 51, 52, 53, 56, 58, 59, 60, 61).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/13", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 14, "from": 10, "beatId": "5dda647e-e3c1-4360-9757-fc347cc61491", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents data and results from clinical trials, including AB-729-001 (p10-14).", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "traction", "function": "analyze_data", "notes": "Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/14", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 14, "from": 10, "beatId": "5dda647e-e3c1-4360-9757-fc347cc61491", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents data and results from clinical trials, including AB-729-001 (p10-14).", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "appendix_disclosure", "function": "summarize", "notes": "The slide uses a bulleted list with custom circular icons to present clinical safety findings.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/15", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "key_takeaways", "function": "summarize", "notes": "Data presented at AASLD 2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/16", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline-based process diagram to illustrate the clinical trial flow.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/17", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide outlines a clinical trial design with two main arms involving AB-729, VTP-300, and optional Nivolumab.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/18", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "other", "function": "cite_precedent", "notes": "The slide details a specific licensing deal, including financial terms and partner background.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/19", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a three-column layout to explain the scientific basis and benefits of the drug.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/20", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-20", "loopMatches": [ { "to": 22, "from": 20, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "660159c2-70d4-4fb9-adcd-06670ff0292c", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-101 and AB-161, as potential solutions (p20-22).", "position": 1, "objective": "What are the key challenges in treating HBV?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.6, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "traction", "function": "show_traction", "notes": "Includes IC50 value and IFN-y fold increase data from patient samples.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/21", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-21", "loopMatches": [ { "to": 22, "from": 20, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "660159c2-70d4-4fb9-adcd-06670ff0292c", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-101 and AB-161, as potential solutions (p20-22).", "position": 1, "objective": "What are the key challenges in treating HBV?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.6, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a three-column layout to highlight the core benefits of the product.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/22", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-22", "loopMatches": [ { "to": 22, "from": 20, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "660159c2-70d4-4fb9-adcd-06670ff0292c", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-101 and AB-161, as potential solutions (p20-22).", "position": 1, "objective": "What are the key challenges in treating HBV?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.6, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "traction", "function": "show_traction", "notes": "Includes both longitudinal efficacy data (line chart) and pharmacokinetic data (bar charts) comparing plasma vs liver concentrations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/23", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "context", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/24", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "solution", "function": "present_solution", "notes": "The slide maps the viral genome to specific drug targets and highlights partnerships with X-Chem and Proteros.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/25", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "solution", "function": "present_solution", "notes": "The slide highlights key therapeutic advantages of the candidate drug.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/26", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-26", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "timeline", "function": "plan_implementation", "notes": "The slide uses a table to present a timeline of clinical milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/27", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-27", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-7472-72bc-8651-e49cc0d0319c", "docSlug": "c2a880ad0c526527fe8aa49c40270224", "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides", "authorId": "arbutus-biopharma", "authorName": "Arbutus Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "closing_ask", "function": "state_next_steps", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/28", "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c", "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-28", "loopMatches": [], "arcBeatMatches": [ { "to": 28, "from": 8, "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 28, "from": 17, "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/4Tt5xQ4n_9C1nDQVSEypoy3iWrWwt56g4aqbgs53g5s/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMDE0ZTVhZTEzNjE0OTVjM2IyNDlhNzU0YmEwZGZhZS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/1", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/StBmOjaTqCPkazd9Sa3oEl611vpW1hRg33Qi38wmecg/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMDE0ZTVhZTEzNjE0OTVjM2IyNDlhNzU0YmEwZGZhZS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/_k_IULnYhUpM5keq0SgB7MixRLyIcnyB-tqvzFrAXCE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMDE0ZTVhZTEzNjE0OTVjM2IyNDlhNzU0YmEwZGZhZS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/2-qFX9_MEaZPFFh9Go5j9KFICUWDwVSHt603bqxcv0E/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xMDE0ZTVhZTEzNjE0OTVjM2IyNDlhNzU0YmEwZGZhZS9wMDAxLnBuZw" }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/2", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "cover", "function": "establish_context", "notes": "The slide uses a thematic background with a network/molecular graphic overlay.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/3", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-3", "loopMatches": [ { "to": 9, "from": 3, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715", "evidence": "The presentation sets up the current situation and unmet needs.", "position": 0, "objective": "Why now is the right time for argenx SE's mission", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "thesis_headline", "function": "present_solution", "notes": "The slide uses a circular graphic element to emphasize the 'revolution' in autoimmunity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/4", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-4", "loopMatches": [ { "to": 9, "from": 3, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715", "evidence": "The presentation sets up the current situation and unmet needs.", "position": 0, "objective": "Why now is the right time for argenx SE's mission", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "key_messages", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/5", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-5", "loopMatches": [ { "to": 9, "from": 3, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715", "evidence": "The presentation sets up the current situation and unmet needs.", "position": 0, "objective": "Why now is the right time for argenx SE's mission", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a hub-and-spoke style layout with a central mission statement and four surrounding strategic pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/6", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-6", "loopMatches": [ { "to": 9, "from": 3, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715", "evidence": "The presentation sets up the current situation and unmet needs.", "position": 0, "objective": "Why now is the right time for argenx SE's mission", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses a waterfall-style bar chart to show quarterly revenue progression, though it is technically a standard bar chart.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/7", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-7", "loopMatches": [ { "to": 9, "from": 3, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715", "evidence": "The presentation sets up the current situation and unmet needs.", "position": 0, "objective": "Why now is the right time for argenx SE's mission", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a combination of clinical trial charts and a logo-grid of scientific journals to establish credibility.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/8", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-8", "loopMatches": [ { "to": 9, "from": 3, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715", "evidence": "The presentation sets up the current situation and unmet needs.", "position": 0, "objective": "Why now is the right time for argenx SE's mission", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a circular cluster diagram to represent four strategic pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/9", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-9", "loopMatches": [ { "to": 9, "from": 3, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "0afda9f0-b287-4237-b0f5-6a95694c5715", "evidence": "The presentation sets up the current situation and unmet needs.", "position": 0, "objective": "Why now is the right time for argenx SE's mission", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "propose_solution", "function": "present_solution", "notes": "The slide uses a hub-and-spoke style diagram to categorize commercial growth drivers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/10", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-10", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "other", "function": "establish_context", "notes": "The slide uses a hub-and-spoke visual metaphor to link the 'Pioneer FcRn class of medicines' to a list of specific autoantibodies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/11", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-11", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a pyramid-like structure to display patient counts for different diseases, with 'clinical' highlighted in the top right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/12", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-12", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline-based layout to communicate clinical development progress and market opportunity size.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/13", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-13", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "key_messages", "function": "present_solution", "notes": "The slide uses a visual representation of an antibody structure to explain the 'sweeping' mechanism.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/14", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-14", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "other", "function": "analyze_data", "notes": "Includes immunofluorescence microscopy images and bar charts showing tidal volume and respiratory rate metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/15", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-15", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "other", "function": "present_solution", "notes": "The slide illustrates the neuromuscular junction mechanism and the clinical trial progression from healthy volunteers to patients with CMS and MuSK MG.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/16", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-16", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "key_messages", "function": "present_framework", "notes": "The slide uses a horizontal layout of four circular icons with corresponding text blocks below, representing a portfolio segmentation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/17", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-17", "loopMatches": [ { "to": 17, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "7e79228a-9d20-4cb5-bd69-2e79252b8cfc", "evidence": "The presentation presents the company's solution and pipeline.", "position": 1, "objective": "The company's solution and pipeline as a big bet for growth", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "other", "function": "establish_context", "notes": "The slide uses a network-like background with lines connecting various logos, suggesting a collaborative ecosystem.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/18", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-18", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "timeline", "function": "plan_implementation", "notes": "The slide uses a dual-section layout to separate commercial regulatory events from clinical trial data readouts and study initiations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/19", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-19", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "other", "function": "other", "notes": "The diagram features five values: Co-Creation, Empowerment, Excellence, Humility, and Innovation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/20", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-20", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "roadmap", "function": "plan_implementation", "notes": "The chart uses a horizontal bar format to represent clinical trial stages (Preclinical to Commercial) for multiple indications under four main programs (VYVGART, Efgartigimod, ARGX-117, ARGX-119).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/21", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-753e-742e-8482-2e45ed67d022", "docSlug": "1014e5ae1361495c3b249a754ba0dfae", "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "other", "function": "present_framework", "notes": "The slide uses a process flow diagram to illustrate the clinical trial methodology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-753e-742e-8482-2e45ed67d022/22", "deckHref": "/decks/019de074-753e-742e-8482-2e45ed67d022", "deckAnchorHref": "/decks/019de074-753e-742e-8482-2e45ed67d022#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-75df-721c-9ba8-ef853b3cc1f4", "docSlug": "a34e905d0b94a260f47535631eefe11f", "documentTitle": "argenx SE | Results Presentation Deck | 11 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/aUlWVoNxgM4XIGcu_4CoYwcewR_Ev9Uz5TxTrFFbg-8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hMzRlOTA1ZDBiOTRhMjYwZjQ3NTM1NjMxZWVmZTExZi9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-75df-721c-9ba8-ef853b3cc1f4/1", "deckHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4", "deckAnchorHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/LIMMXoB-tlwp2IL9WKhn4zLs0yDLFoxpKTucybtpkTs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hMzRlOTA1ZDBiOTRhMjYwZjQ3NTM1NjMxZWVmZTExZi9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/XCNFUj38ji5zFtZp8nyKhyHk7lnVPopPENF-6ly-fZ0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hMzRlOTA1ZDBiOTRhMjYwZjQ3NTM1NjMxZWVmZTExZi9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/egohHOqIDtLEO3bZ_zqgp1MHW5sj7MOA-Rm3PES-VT4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hMzRlOTA1ZDBiOTRhMjYwZjQ3NTM1NjMxZWVmZTExZi9wMDAxLnBuZw" }, { "docId": "019de074-75df-721c-9ba8-ef853b3cc1f4", "docSlug": "a34e905d0b94a260f47535631eefe11f", "documentTitle": "argenx SE | Results Presentation Deck | 11 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-75df-721c-9ba8-ef853b3cc1f4/2", "deckHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4", "deckAnchorHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-75df-721c-9ba8-ef853b3cc1f4", "docSlug": "a34e905d0b94a260f47535631eefe11f", "documentTitle": "argenx SE | Results Presentation Deck | 11 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a central Venn-like diagram of four circles to organize key company achievements and focus areas.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-75df-721c-9ba8-ef853b3cc1f4/3", "deckHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4", "deckAnchorHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "966a48b9-880d-4456-9403-a7f11ebca559", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-1", "evidence": "Slides 3-5 provide an overview of the company's current position and achievements.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-75df-721c-9ba8-ef853b3cc1f4", "docSlug": "a34e905d0b94a260f47535631eefe11f", "documentTitle": "argenx SE | Results Presentation Deck | 11 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a combination of line charts for clinical data and a list for safety metrics, followed by a logo-grid of scientific journals.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-75df-721c-9ba8-ef853b3cc1f4/4", "deckHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4", "deckAnchorHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "966a48b9-880d-4456-9403-a7f11ebca559", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-1", "evidence": "Slides 3-5 provide an overview of the company's current position and achievements.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-75df-721c-9ba8-ef853b3cc1f4", "docSlug": "a34e905d0b94a260f47535631eefe11f", "documentTitle": "argenx SE | Results Presentation Deck | 11 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "key_takeaways", "function": "summarize", "notes": "The diagram uses a clover-like circular layout to represent interconnected strategic pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de074-75df-721c-9ba8-ef853b3cc1f4/5", "deckHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4", "deckAnchorHref": "/decks/019de074-75df-721c-9ba8-ef853b3cc1f4#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "966a48b9-880d-4456-9403-a7f11ebca559", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-1", "evidence": "Slides 3-5 provide an overview of the company's current position and achievements.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }